22-05-2024, 12:00

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Globe Newswire22-05-2024, 12:00
7-05-2024, 12:00

Sandoz reports first quarter 2024 sales
Globe Newswire7-05-2024, 12:00
30-04-2024, 17:25

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
Globe Newswire30-04-2024, 17:25
30-04-2024, 12:00

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
Globe Newswire30-04-2024, 12:00
22-04-2024, 12:00

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Globe Newswire22-04-2024, 12:00
21-03-2024, 20:00

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
Globe Newswire21-03-2024, 20:00
29-02-2024, 13:00

Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
Globe Newswire29-02-2024, 13:00
1-02-2024, 13:15

Sandoz announces changes in the Board of Directors
Globe Newswire1-02-2024, 13:15
31-01-2024, 13:00

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
Globe Newswire31-01-2024, 13:00
22-01-2024, 13:00

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
Globe Newswire22-01-2024, 13:00
21-11-2023, 13:00

Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
Globe Newswire21-11-2023, 13:00
4-10-2023, 12:05

Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines
Globe Newswire4-10-2023, 12:05